Wed, 16 Oct 2013 | MBO/MBI
Social housing contractor Forrest has been subjected to a secondary management buyout deal, with a partial exit for private equity outfit LDC.
Palatine Private Equity has put in £16 million to secure a significant minority stake in the business, which will give Palatine and LDC a combined majority stake.
Santander Structured Finance and RBS contributed senior debt and working capital facilities of £26 million for the sale.
Based in Bolton and with a responsive maintenance division in Leeds, Forrest provides essential refurbishment and maintenance to the social housing sector across the North of England. It has revenues exceeding £100 million, an order book to the value of £1.2 billion and a 500-strong workforce.
Palatine managing partner Gary Tipper, partner Ed Fazakerley and investment manager James Winterbottom worked on the transaction and Tipper and Fazakerley will join the Forrest board as non-executive directors. Current Forrest chairman Robert Morgan is exiting the business.
Lee McCarren, chief executive at Forrest, said: “LDC, lead by Jonathan Bell, have been a hugely supportive partner for the business over the past six years. With Palatine alongside us as an additional investor, we can continue to drive improvements in the quality of our customer service offering, as well as developing more new and complementary service lines.”
“This on-going strategy has been the key to our many consecutive years’ growth and to our strong, long-term customer relationships.”
Established in 1955 as Herbert T Forrest, the company was rebranded as Forrest in 2010. Its social housing clients include Bolton at Home, Salix Homes and Blackpool Coastal Homes.
__________________________________________________________________________
Related information:
Avoiding the 10 main deal-breakers when buying a business
This unique and renowned freehold bar and restaurant in the heart of York City Centre offers over 250 covers across its spacious interior, pavement seating, and a rare rooftop terrace.
FREEHOLD
A well established and strongly profitable engineering business, located in the Midlands. The company will be an attractive acquisition for both a larger trade buyer and also those looking for a stable engineering business.
This European pharmacy manufacturer specialises in providing custom clinical trial batches for leading pharmacy companies across the continent, playing a crucial role in their R&D efforts.
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.